CORD is truly indebted to all of the individuals, patient organizations, and corporations that contribute to advancing rare disease in Canada. This year, CORD’s 5th Annual Rarity Awards will once again recognize those who have demonstrated outstanding commitment and achievements toward overcoming the challenges of rare diseases and improving people’s lives. The nomination process is open to everyone. You are invited to submit a nomination for any or all of the award categories.
The award winners will be honoured at the CORD Rare Disease Day Gala on March 30, 2017 in Vancouver.
Deadline is: February 15, 2017.
To submit a nomination, please go to: www.surveymonkey.com/r/rddawards2017
Rare Disease Leadership Award
This award is presented to an individual who has demonstrated outstanding leadership in the rare disease community.
Policy Maker Award
This award is presented to a policy maker whose dedication and commitment to rare diseases has made a difference to the rare disease community.
CORD Volunteer Award
This award is presented to an individual who has made an outstanding contribution to CORD and the rare disease community on a volunteer basis.
CORD Youth Leadership Award
This award is given to celebrate and recognize the contributions and achievements of young people in the rare disease community and impact in shaping the future.
This award is presented to a distinguished researcher whose career represents a unique blend of scientific excellence and support of the patient community.
Patient Organization Award
This award is presented to a CORD affiliate member group making outstanding contribution in patient support or advocacy.
This award is presented to a leading company who is dedicated and committed to developing and providing treatments to improve the lives of those with rare diseases.
November 17, 2017
Toronto & Webcast
ARE YOU READY? On January 1, 2018, Ontario will roll out OHIP+. The transition will apply to all kids and youths under 25, including those currently on private drug insurance and including all drugs, including those currently provided under EAP. The Canadian Organization for Rare Disorders has received many questions about issues that could affect a smooth transition. What if the child’s drug is not listed in ODP or EAP? What if the criteria between the current private plan and OHIP+ are different? What about the private support program? What if … what if …? CORD invites patient groups, clinicians, industry, insurers, and other stakeholders to join Vivian Leong, A/Director for OHIP+ to work through potential issues to ensure a SMOOTH transition on January 1st and beyond. Please join us for a F2F and Webcast working session on November 17, 2017 from 9:00 am – 11:30 am. Space in person is strictly limited to 30 persons but attendance by Webcast is virtually unlimited.